Product Description
Oral Insulin Capsule for T2DM. OramedÕs oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. (Sourced from: https://www.oramed.com/pipeline/ormd-0801-type-2/)
Mechanisms of Action: INSR Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oramed
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ORA-D-013-3 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2026-04-25 |
|
| CTR20201644 | P3 |
Recruiting |
Type 2 Diabetes |
None |